Predicting Response to Neoadjuvant Chemotherapy in Bladder Cancer

Giovanni Motterle, Jack R. Andrews, Alessandro Morlacco, R. Jeffrey Karnes

Research output: Contribution to journalReview article

Abstract

Context: Neoadjuvant chemotherapy (NAC) is recommended prior to radical cystectomy in the setting of muscle-invasive bladder cancer. Despite a 5–10% survival benefit, some patients do not respond to NAC. Identification of the nonresponders could avoid side effects and delay in surgery. Objective: The objective of this review is to summarize the latest evidence regarding predictors of NAC response. Evidence acquisition: MEDLINE, Embase, and the Cochrane Library databases were searched for published studies including clinical, pathological, molecular, and imaging tests or factors that can be applied before or during NAC to predict its results. Evidence synthesis: Patient characteristics and imaging techniques seem to have minimal utility to predict NAC response. Only advanced magnetic resonance imaging techniques seem to have a potential role. There is insufficient evidence to suggest a change in NAC paradigm for variant histology, whereas the most promising results come from molecular characterization of tumors. Conclusions: No validated instrument currently exists to predict NAC response. While awaiting further evidence, no strong recommendation can be made toward a shift in paradigm. Patient summary: The most effective and aggressive treatment for muscle-invasive bladder cancer is radical cystectomy preceded by effective neoadjuvant chemotherapy. In this paper, we reviewed the current literature and published evidence to identify predictors of response to neoadjuvant chemotherapy for muscle-invasive bladder cancer. To date, no instrument exists to predict which patients will respond to neoadjuvant chemotherapy.

Original languageEnglish (US)
JournalEuropean Urology Focus
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Urinary Bladder Neoplasms
Drug Therapy
Cystectomy
Muscles
Molecular Imaging
MEDLINE
Libraries
Histology
Magnetic Resonance Imaging
Databases
Survival

Keywords

  • Bladder cancer
  • Molecular subtypes
  • Muscle-invasive bladder cancer
  • Neoadjuvant chemotherapy
  • Predictors of response

ASJC Scopus subject areas

  • Urology

Cite this

Predicting Response to Neoadjuvant Chemotherapy in Bladder Cancer. / Motterle, Giovanni; Andrews, Jack R.; Morlacco, Alessandro; Karnes, R. Jeffrey.

In: European Urology Focus, 01.01.2019.

Research output: Contribution to journalReview article

Motterle, Giovanni ; Andrews, Jack R. ; Morlacco, Alessandro ; Karnes, R. Jeffrey. / Predicting Response to Neoadjuvant Chemotherapy in Bladder Cancer. In: European Urology Focus. 2019.
@article{6f9da96521ee493594f0a7700edad437,
title = "Predicting Response to Neoadjuvant Chemotherapy in Bladder Cancer",
abstract = "Context: Neoadjuvant chemotherapy (NAC) is recommended prior to radical cystectomy in the setting of muscle-invasive bladder cancer. Despite a 5–10{\%} survival benefit, some patients do not respond to NAC. Identification of the nonresponders could avoid side effects and delay in surgery. Objective: The objective of this review is to summarize the latest evidence regarding predictors of NAC response. Evidence acquisition: MEDLINE, Embase, and the Cochrane Library databases were searched for published studies including clinical, pathological, molecular, and imaging tests or factors that can be applied before or during NAC to predict its results. Evidence synthesis: Patient characteristics and imaging techniques seem to have minimal utility to predict NAC response. Only advanced magnetic resonance imaging techniques seem to have a potential role. There is insufficient evidence to suggest a change in NAC paradigm for variant histology, whereas the most promising results come from molecular characterization of tumors. Conclusions: No validated instrument currently exists to predict NAC response. While awaiting further evidence, no strong recommendation can be made toward a shift in paradigm. Patient summary: The most effective and aggressive treatment for muscle-invasive bladder cancer is radical cystectomy preceded by effective neoadjuvant chemotherapy. In this paper, we reviewed the current literature and published evidence to identify predictors of response to neoadjuvant chemotherapy for muscle-invasive bladder cancer. To date, no instrument exists to predict which patients will respond to neoadjuvant chemotherapy.",
keywords = "Bladder cancer, Molecular subtypes, Muscle-invasive bladder cancer, Neoadjuvant chemotherapy, Predictors of response",
author = "Giovanni Motterle and Andrews, {Jack R.} and Alessandro Morlacco and Karnes, {R. Jeffrey}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.euf.2019.10.016",
language = "English (US)",
journal = "European Urology Focus",
issn = "2405-4569",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Predicting Response to Neoadjuvant Chemotherapy in Bladder Cancer

AU - Motterle, Giovanni

AU - Andrews, Jack R.

AU - Morlacco, Alessandro

AU - Karnes, R. Jeffrey

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Context: Neoadjuvant chemotherapy (NAC) is recommended prior to radical cystectomy in the setting of muscle-invasive bladder cancer. Despite a 5–10% survival benefit, some patients do not respond to NAC. Identification of the nonresponders could avoid side effects and delay in surgery. Objective: The objective of this review is to summarize the latest evidence regarding predictors of NAC response. Evidence acquisition: MEDLINE, Embase, and the Cochrane Library databases were searched for published studies including clinical, pathological, molecular, and imaging tests or factors that can be applied before or during NAC to predict its results. Evidence synthesis: Patient characteristics and imaging techniques seem to have minimal utility to predict NAC response. Only advanced magnetic resonance imaging techniques seem to have a potential role. There is insufficient evidence to suggest a change in NAC paradigm for variant histology, whereas the most promising results come from molecular characterization of tumors. Conclusions: No validated instrument currently exists to predict NAC response. While awaiting further evidence, no strong recommendation can be made toward a shift in paradigm. Patient summary: The most effective and aggressive treatment for muscle-invasive bladder cancer is radical cystectomy preceded by effective neoadjuvant chemotherapy. In this paper, we reviewed the current literature and published evidence to identify predictors of response to neoadjuvant chemotherapy for muscle-invasive bladder cancer. To date, no instrument exists to predict which patients will respond to neoadjuvant chemotherapy.

AB - Context: Neoadjuvant chemotherapy (NAC) is recommended prior to radical cystectomy in the setting of muscle-invasive bladder cancer. Despite a 5–10% survival benefit, some patients do not respond to NAC. Identification of the nonresponders could avoid side effects and delay in surgery. Objective: The objective of this review is to summarize the latest evidence regarding predictors of NAC response. Evidence acquisition: MEDLINE, Embase, and the Cochrane Library databases were searched for published studies including clinical, pathological, molecular, and imaging tests or factors that can be applied before or during NAC to predict its results. Evidence synthesis: Patient characteristics and imaging techniques seem to have minimal utility to predict NAC response. Only advanced magnetic resonance imaging techniques seem to have a potential role. There is insufficient evidence to suggest a change in NAC paradigm for variant histology, whereas the most promising results come from molecular characterization of tumors. Conclusions: No validated instrument currently exists to predict NAC response. While awaiting further evidence, no strong recommendation can be made toward a shift in paradigm. Patient summary: The most effective and aggressive treatment for muscle-invasive bladder cancer is radical cystectomy preceded by effective neoadjuvant chemotherapy. In this paper, we reviewed the current literature and published evidence to identify predictors of response to neoadjuvant chemotherapy for muscle-invasive bladder cancer. To date, no instrument exists to predict which patients will respond to neoadjuvant chemotherapy.

KW - Bladder cancer

KW - Molecular subtypes

KW - Muscle-invasive bladder cancer

KW - Neoadjuvant chemotherapy

KW - Predictors of response

UR - http://www.scopus.com/inward/record.url?scp=85075351724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075351724&partnerID=8YFLogxK

U2 - 10.1016/j.euf.2019.10.016

DO - 10.1016/j.euf.2019.10.016

M3 - Review article

C2 - 31708469

AN - SCOPUS:85075351724

JO - European Urology Focus

JF - European Urology Focus

SN - 2405-4569

ER -